
Competing interests: None declared.
DOI:10.1503/cmaj.1041678

Corrections

The last name of the author of a recent Left Atrium article1 was published incorrectly. The author’s name is Alejandro R. Jadad. The online version was corrected.

Reference
DOI:10.1503/cmaj.1041680

In 2 recent articles,1,2 the authors’ omitted relevant information regarding their competing interests; their interests should have been listed as follows:

None declared for Peter Bogaty or Blair O’Neill. Paul Armstrong has received research funding from Hoffman-La Roche, Aventis and Boehringer Ingelheim, and educational and consultant funding from Hoffmann-La Roche and Aventis. Paul Dorian has received speaker fees from Guidant Corp., Medtronic Inc. and St. Jude Medical Inc. Dr. Buller has received research support from Guidant Corp. and Cordis Johnson & Johnson, consultant fees from Guidant Corp. and Aventis, and speaker fees from Hoffman-La Roche.

References

The authors of a recent research article1 mistakenly omitted Joelle Bradley from their list of authors. She contributed to the development of the questionnaire, study design and data collection. At the time of her contribution she was a medical student at the University of Calgary. She has recently finished her residency in family medicine at the University of Alberta.

Reference
DOI:10.1503/cmaj.1041682

The DOI published in a recent news item1 was mistakenly listed as 10.1503/cmaj.1041056. It should be 10.1503/cmaj.1041506.

Reference
DOI:10.1503/cmaj.1041683

In a recent article1 there was a typographical error pertaining to the number needed to treat (NNT) for the SCD-HeFT trial. It should read NNT 14 rather than 1.

Reference
1. Davis DR, Tang ASL. Implantable cardioverter defibrillators: therapy against Canada’s leading killer. CMAJ 2004;171(9):1037-8.
DOI:10.1503/cmaj.1041689